UPC after one month: Life sciences cases
Monticello / Shutterstock
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.
The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.
As confirmed by lawyers to WIPR, the German division of French drugmaker Sanofi filed a revocation action against the US pharma company before the court’s central division in Munich citing patent number EP 3 666 797.
It marks a new twist in the global litigation waged between the two companies over antibody patents that wound its way to the US Supreme Court last month.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Amgen, court, patent, Sanofi, opt-outs, revocation, Unified, pan-European, French, pharma, venue